Current Report Filing (8-k)
March 20 2017 - 9:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): March 20, 2017
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number,
including area code:
(212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Ference Kesner LLP
61 Broadway
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01
|
Regulation FD Disclosure.
|
Tonix Pharmaceuticals Holding Corp. (the
“Company”) intends to utilize two updated investor presentations to conduct meetings with investors, stockholders and
analysts and at investor conferences, and which the Company intends to place on its website, which may contain non-public information. Copies
of the two presentations are filed as Exhibits 99.01 and 99.02.
The information contained in Item 7.01
of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02, is furnished pursuant to, and shall not be deemed to be
"filed" for the purposes of, Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section. The information contained in Item 7.01 of this Current Report shall not be incorporated
by reference into any registration statement or any other document filed pursuant to the Securities Act of 1933, as amended, except
as otherwise expressly stated in such filing. By filing this Current Report on Form 8-K and furnishing the information
contained in this Item 7.01, including Exhibits 99.01 and 99.02, the Company makes no admission as to the materiality of any such
information that it is furnishing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.01
|
Corporate Presentation by the Company for March 2017*
|
|
99.02
|
Short Corporate Presentation by the Company for March 2017*
|
* Furnished herewith.
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING CORP.
|
Date: March 20, 2017
|
By:
|
/s/ SETH LEDERMAN
|
|
Seth Lederman
|
|
Chief Executive Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024